Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
J-Star Holding completes $5 million IPO on NASDAQ
-
J-Star Holding Announces Closing of $5.0 Million Initial Public Offering
-
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
-
Maxim Group Starts Galaxy Digital (GLXY) at Buy
-
Asia Go IPO Summit 2025 Unveils Speaker Lineup and Agenda
-
SOS Limited prices $7.5 million registered direct offering at $3.50 per share
-
SOS Limited Announces Pricing of $7.5 Million Registered Direct Offering
-
J-Star prices $5 million IPO at $4 per share on NASDAQ
-
J-Star Holding Announces Pricing of $5.0 Million Initial Public Offering
-
Strategy closes $2.521 billion IPO for Bitcoin treasury expansion
-
Strategy Announces Closing of $2.521 Billion STRC Stock Initial Public Offering
-
IceCure completes $10 million rights offering, twice oversubscribed
-
AIM ImmunoTech prices $8 million public offering at $4 per share
-
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
-
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
-
AmpliTech Group expects growth from U.S.-EU semiconductor trade deal
-
TNL MEDIAGENE reports first half progress since NASDAQ listing
-
AmpliTech Group Poised to Benefit from U.S. – EU Semiconductor Trade Deal
-
TNL Mediagene Issues Shareholder Letter Recapping Active and Transformative H1 2025 and Provides Corporate Update
-
Xtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity
-
Roadzen prices $2.25 million registered direct offering at $1.30 per share
-
Roadzen Announces Pricing of $2.25 Million Registered Direct Offering of Ordinary Shares
-
AmpliTech Group's AGMDC division joins texoma semiconductor tech hub
-
AmpliTech Group’s AGMDC Division Joins the Texoma Semiconductor Tech Hub Initiative (TSTH)
-
Strategy prices $2.5 billion preferred stock offering at $90 per share
-
Strategy Announces Pricing of Initial Public Offering of STRC Stock
-
U Power prices $1.4 million registered direct offering at $2.50 per share
-
U Power Announces Pricing of $1.4 Million Registered Direct Offering
-
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
-
AmpliTech receives $5 million in 5G orders from North American carrier
-
AmpliTech Group Receives $3 Million in New Orders Beyond $40 Million LOI, Plus $2 Million Within LOI from Tier-1 North American MNO
-
Maxim Group Downgrades Brainstorm Cell Therapeutics (BCLI) to Hold
-
OceanPal closes $18 million public offering
-
OceanPal Inc. Announces Closing of Upsized US$18.0 Million Public Offering
-
Oriental Rise prices $6.9 million public offering at $0.47 per unit
-
Oriental Rise Holdings Limited Announces Pricing of $6.9 Million Public Offering
-
Maxim Group Starts Adocia (ADOC:FP) (ADOCY) at Buy
-
Draganfly closes $25 million registered direct offering
-
Draganfly Announces Closing of US$25.0 Million Registered Direct Offering
-
Maxim Group LLC Expands Equity Sales and Trading with Strategic Hire of Michael Chrisman
-
OceanPal prices upsized $18 million public offering at $1.64 per unit
-
OceanPal Inc. Announces Pricing of Upsized US$18.0 Million Public Offering
-
NioCorp closes $45 million public offering of common shares
-
NioCorp Announces Closing of $45.0 Million Public Offering of Common Shares
-
Draganfly raises $25 million through registered direct offering
-
Draganfly Announces Pricing of US$25.0 Million Registered Direct Offering
-
Maxim Group Starts Akari Therapeutics (AKTX) at Buy
-
Citius Oncology closes $9 million public offering
-
Citius Oncology Announces Closing of $9.0 Million Public Offering
-
Citius Oncology Announces Closing of $9.0 Million Public Offering

